An initial carbamazepine concentration may initially be supratherapeutic, therapeutic, or even subtherapeutic only to persist to rise over time. The aim of this study was to report the frequency of toxic carbamazepine concentrations continuing to rise and to estimate how often an initially therapeutic or subtherapeutic concentration misrepresents the potential toxicity of an acute carbamazepine overdose. An 8-year retrospective search of all carbamazepine exposures reported to the Illinois Poison Center (January 1, 2001 through December 31, 2008) was reviewed. Inclusion criteria were acute poisonings with a documented carbamazepine concentration of >12 &mgr;g/mL at any time. Those with initial concentrations of >12 &mgr;g/mL that subsequently increased over time were recorded. Additionally, those cases that initially had therapeutic (4–12 &mgr;g/mL) or subtherapeutic (<4 &mgr;g/mL) concentration were identified. Descriptive statistics were used to analyze the data. A total of 1424 cases were reported. Of the 523 patients with documented concentrations of >12 &mgr;g/mL, 93 patients (17.8%) had initial carbamazepine concentrations >12 &mgr;g/mL and continued to rise. Sixteen patients (3.5%) had initial carbamazepine concentrations that were therapeutic (4–12 &mgr;g/mL) and 7 patients (1.3%) had initial carbamazepine concentrations <4 &mgr;g/mL before rising >12 &mgr;g/mL. Certain patients had progressive decreases in level of consciousness corresponding to increasing carbamazepine concentrations. Additionally, several patients with initial levels of therapeutic or subtherapeutic concentration later became comatose and required ventilator management. Initial serum carbamazepine concentrations can be misleading. Serial measurements documenting a declining carbamazepine concentration or prolonged observation are recommended when managing these overdoses.
[1]
S. Simpson.
Pharmacobezoars described and demystified
,
2011,
Clinical toxicology.
[2]
D. Spyker,et al.
2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report
,
2010,
Clinical toxicology.
[3]
D. Ryan,et al.
Delayed salicylate toxicity with undetectable initial levels after large-dose aspirin ingestion.
,
2009,
The American journal of emergency medicine.
[4]
J. Petersen,et al.
Efficacy of hemodialysis and charcoal hemoperfusion in carbamazepine overdose
,
2008,
Clinical toxicology.
[5]
N. Brahmi,et al.
Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning.
,
2006,
The American journal of emergency medicine.
[6]
R. Clark,et al.
Delayed valproic acid toxicity: a retrospective case series.
,
2002,
Annals of emergency medicine.
[7]
A. Graudins,et al.
Massive overdose with controlled-release carbamazepine resulting in delayed peak serum concentrations and life-threatening toxicity.
,
2002,
Emergency medicine.
[8]
W. Szymczak,et al.
Carbamazepine Poisoning: Elimination Kinetics and Quantitative Relationship with Carbamazepine 10,11-Epoxide
,
2002,
Journal of toxicology. Clinical toxicology.
[9]
L. Durelli,et al.
Carbamazepine Toxicity and Poisoning
,
1989,
Medical toxicology and adverse drug experience.